Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (381) 381
life sciences & biomedicine (376) 376
humans (371) 371
canagliflozin (340) 340
diabetes mellitus, type 2 - drug therapy (305) 305
diabetes (222) 222
type 2 diabetes (204) 204
male (198) 198
female (192) 192
hypoglycemic agents - therapeutic use (192) 192
middle aged (170) 170
hypoglycemic agents - adverse effects (167) 167
glucose (159) 159
canagliflozin - therapeutic use (155) 155
endocrinology & metabolism (155) 155
sodium-glucose transporter 2 - antagonists & inhibitors (148) 148
canagliflozin - adverse effects (131) 131
aged (127) 127
glucosides - therapeutic use (125) 125
type 2 diabetes mellitus (107) 107
diabetes mellitus (101) 101
pharmacology & pharmacy (98) 98
adult (97) 97
glucosides - adverse effects (96) 96
dapagliflozin (95) 95
treatment outcome (91) 91
diabetes mellitus, type 2 - blood (89) 89
hypoglycemic agents - administration & dosage (89) 89
general & internal medicine (85) 85
medicine, general & internal (85) 85
dextrose (84) 84
empagliflozin (84) 84
blood pressure (81) 81
sodium (76) 76
thiophenes - therapeutic use (76) 76
blood glucose - drug effects (75) 75
clinical trials (74) 74
drug therapy (74) 74
benzhydryl compounds - therapeutic use (70) 70
blood glucose - metabolism (70) 70
sglt2 inhibitor (68) 68
canagliflozin - administration & dosage (66) 66
care and treatment (63) 63
double-blind method (62) 62
thiophenes - adverse effects (62) 62
risk factors (58) 58
body weight (57) 57
internal medicine (56) 56
diabetes mellitus, type 2 - complications (54) 54
analysis (51) 51
glucosides - administration & dosage (51) 51
insulin (51) 51
hypoglycemic agents - pharmacology (50) 50
diabetes therapy (49) 49
sodium-glucose transporter 2 inhibitors - adverse effects (48) 48
glycated hemoglobin a - metabolism (47) 47
diabetes mellitus, type 2 - metabolism (45) 45
dose-response relationship, drug (45) 45
randomized controlled trials as topic (45) 45
benzhydryl compounds - adverse effects (44) 44
drug therapy, combination (44) 44
cardiovascular disease (43) 43
hemoglobin (43) 43
medicine & public health (43) 43
patients (43) 43
sodium-glucose transporter 2 inhibitors - therapeutic use (43) 43
abridged index medicus (42) 42
blood pressure - drug effects (42) 42
hypoglycemic agents (42) 42
sodium-glucose transporter 2 - metabolism (42) 42
endocrinology (41) 41
thiophenes - administration & dosage (41) 41
glucosides - pharmacology (40) 40
hypoglycemia (37) 37
medical research (36) 36
medicine, research & experimental (36) 36
research & experimental medicine (36) 36
review (36) 36
safety (36) 36
glucose transporter (35) 35
body mass index (34) 34
canagliflozin - pharmacology (34) 34
metformin (34) 34
research (34) 34
sodium-glucose transporter 2 inhibitors (34) 34
cardiovascular diseases (33) 33
diabetes mellitus, type 2 - physiopathology (33) 33
kidneys (33) 33
sodium glucose co-transporter 2 inhibitor (33) 33
animals (32) 32
glycosylated hemoglobin (32) 32
hyperglycemia (32) 32
studies (32) 32
body weight - drug effects (31) 31
heart failure (31) 31
hypoglycemia - chemically induced (31) 31
kidney diseases (31) 31
young adult (31) 31
complications and side effects (30) 30
kidney - drug effects (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (488) 488
German (5) 5
Chinese (2) 2
Danish (1) 1
French (1) 1
Hungarian (1) 1
Japanese (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
by Lavalle-González, F J and Januszewicz, A and Davidson, J and Tong, C and Qiu, R and Canovatchel, W and Meininger, G
Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Diabetes. Impaired glucose tolerance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study
by Leiter, Lawrence A and Leiter, Lawrence A and Yoon, Kun-Ho and Yoon, Kun-Ho and Arias, Pablo and Arias, Pablo and Langslet, Gisle and Langslet, Gisle and Xie, John and Xie, John and Balis, Dainius A and Balis, Dainius A and Millington, Dawn and Millington, Dawn and Vercruysse, Frank and Vercruysse, Frank and Canovatchel, William and Canovatchel, William and Meininger, Gary and Meininger, Gary
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 355 - 364
Thiophenes - adverse effects | Humans | Middle Aged | Body Weight - drug effects | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Time Factors | Female | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Drug Therapy, Combination | Hypoglycemia - chemically induced | Glucosides - adverse effects | Double-Blind Method | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Canagliflozin | Glucosides - administration & dosage | Weight Loss | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Care and treatment | Usage | Analysis | Clinical trials | Glycemic index | Dosage and administration | Metformin | Prescription drugs | Blood pressure | Diabetes | Patients | Weight | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial
by Wilding, J. P. H and Charpentier, G and Hollander, P and González‐Gálvez, G and Mathieu, C and Vercruysse, F and Usiskin, K and Law, G and Black, S and Canovatchel, W and Meininger, G
International journal of clinical practice (Esher), ISSN 1368-5031, 12/2013, Volume 67, Issue 12, pp. 1267 - 1282
Medicine, General & Internal | Pharmacology & Pharmacy | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Metformin - adverse effects | Dose-Response Relationship, Drug | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Adult | Female | Blood Pressure - drug effects | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Glucosides - adverse effects | Insulin-Secreting Cells - physiology | Double-Blind Method | Drug Administration Schedule | Treatment Outcome | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Adolescent | Lipid Metabolism - drug effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Glucose metabolism | Care and treatment | Clinical trials | Hypoglycemic agents | Glucose | Cholesterol | Dextrose | Diabetes therapy | Patient safety | Pharmacology | Diabetes | Drug therapy | Clinical outcomes | Index Medicus | Endocrinology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
by Watts, Nelson B and Bilezikian, John P and Usiskin, Keith and Edwards, Robert and Desai, Mehul and Law, Gordon and Meininger, Gary
The journal of clinical endocrinology and metabolism, ISSN 0021-972X, 01/2016, Volume 101, Issue 1, pp. 157 - 166
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Age Factors | Double-Blind Method | Humans | Middle Aged | Kaplan-Meier Estimate | Fractures, Bone - epidemiology | Male | Risk | Canagliflozin - adverse effects | Incidence | Dose-Response Relationship, Drug | Cardiovascular Diseases - complications | Canagliflozin - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Accidental Falls | Diabetes Mellitus, Type 2 - complications | Diuretics - adverse effects | Index Medicus | Abridged Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Adverse effects of SGLT2 inhibitors on bone health
by Blau, Jenny E and Taylor, Simeon I
Nature reviews. Nephrology, ISSN 1759-5061, 08/2018, Volume 14, Issue 8, pp. 473 - 474
Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Bone Demineralization, Pathologic - chemically induced | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Bone Density - drug effects | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Fibroblast Growth Factors - blood | Phosphorus - blood | Humans | Vitamin D - analogs & derivatives | Canagliflozin - adverse effects | Parathyroid Hormone - blood | Fractures, Bone - chemically induced | Vitamin D - blood | Osteoporosis | Bones | Research | Health aspects | Risk factors | Side effects | Inhibitor drugs | Vitamin D | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Endogenous glucose production and hormonal changes in response to canagliflozin and liraglutide combination therapy
by Martinez, Robert and Al-Jobori, Hussein and Ali, Ali M and Adams, John and Abdul-Ghani, Muhammad and Triplitt, Curtis and DeFronzo, Ralph A and Cersosimo, Eugenio
Diabetes (New York, N.Y.), ISSN 0012-1797, 06/2018, Volume 67, Issue 6, pp. 1182 - 1189
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Gluconeogenesis - drug effects | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Insulin - blood | Glucagon - blood | Glucagon - antagonists & inhibitors | Glucagon - agonists | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Glucagon-Secreting Cells - drug effects | Insulin-Secreting Cells - metabolism | Canagliflozin - therapeutic use | Glucagon-Secreting Cells - metabolism | Adult | Female | Hypoglycemia - chemically induced | Insulin Secretion | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Reproducibility of Results | Insulin - agonists | Sodium-Glucose Transporter 2 - metabolism | Sodium-Glucose Transporter 2 Inhibitors | Canagliflozin - adverse effects | Down-Regulation - drug effects | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Insulin-Secreting Cells - drug effects | Insulin - chemistry | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - therapeutic use | Membrane Transport Modulators - therapeutic use | Glucagon - metabolism | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Dosage and administration | Research | Drug therapy, Combination | Drug therapy | Liraglutide | Glucagon | Cardiomyopathy | Diabetes mellitus | Clinical trials | Diabetes | Glucose | Epidemiology | Diabetes mellitus (non-insulin dependent) | Insulin | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium-Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes
by Neal, Bruce and Perkovic, Vlado and de Zeeuw, Dick and Mahaffey, Kenneth W and Fulcher, Greg and Ways, Kirk and Desai, Mehul and Shaw, Wayne and Capuano, George and Alba, Maria and Jiang, Joel and Vercruysse, Frank and Meininger, Gary and Matthews, David and CANVAS Trial Collaborative Grp and CANVAS Trial Collaborative Group
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 403 - 411
METFORMIN | GLYCEMIC CONTROL | PLACEBO | MONOTHERAPY | SULFONYLUREA | SITAGLIPTIN | DOUBLE-BLIND | RANDOMIZED-TRIAL | POOLED ANALYSIS | MELLITUS | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glycosuria - chemically induced | Hypovolemia - chemically induced | Thiophenes - adverse effects | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Thiophenes - administration & dosage | Weight Loss - drug effects | Dose-Response Relationship, Drug | Glomerular Filtration Rate - drug effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Female | Blood Pressure - drug effects | Drug Therapy, Combination | Glucosides - adverse effects | Double-Blind Method | Insulin - administration & dosage | Treatment Outcome | Hypoglycemia - drug therapy | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin | Glucosides - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Mycoses - chemically induced | Clinical trials | Prescription drugs | Diabetes | Safety | Drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
by Stenlöf, Kaj and Cefalu, William T and Kim, Kyoung-Ah and Jodar, Esteban and Alba, Maria and Edwards, Robert and Tong, Cindy and Canovatchel, William and Meininger, Gary
Current medical research and opinion, ISSN 0300-7995, 2/2014, Volume 30, Issue 2, pp. 163 - 175
Glycemic control | Body weight reduction | Sodium glucose co-transporter 2 (SGLT2) inhibitor | Phase 3 study | Type 2 diabetes mellitus | Canagliflozin | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Thiophenes - therapeutic use | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Body Weight - drug effects | Male | Pyrazines - therapeutic use | Weight Loss - drug effects | Exercise | Cholesterol, LDL - blood | Female | Glucosides - therapeutic use | Blood Pressure - drug effects | Sitagliptin Phosphate | Hypoglycemia - chemically induced | Glucosides - adverse effects | Placebos - administration & dosage | Triazoles - therapeutic use | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Blood Glucose | Sodium-Glucose Transporter 2 Inhibitors | Treatment Outcome | Diet | Pyrazines - adverse effects | Triglycerides - blood | Cholesterol, HDL - blood | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
by Scheen, André J
Drugs (New York, N.Y.), ISSN 0012-6667, 01/2015, Volume 75, Issue 1, pp. 33 - 59
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Thiophenes - therapeutic use | Glucosides - pharmacology | Thiophenes - adverse effects | Humans | Thiophenes - pharmacology | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Benzhydryl Compounds - adverse effects | Canagliflozin | Glucosides - therapeutic use | Benzhydryl Compounds - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Hypoglycemic Agents - adverse effects | Glucosides - adverse effects
Journal Article
Details down arrow
10. Full Text Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: an expert panel overview of the evidence
by Katsiki, Niki and Dimitriadis, George and Hahalis, George and Papanas, Nikolaos and Tentolouris, Nikolaos and Triposkiadis, Filippos and Tsimihodimos, Vasilios and Tsioufis, Costas and Mikhailidis, Dimitri P and Mantzoros, Christos
Metabolism, clinical and experimental, ISSN 0026-0495, 07/2019, Volume 96, pp. 92 - 100
Empagliflozin | Canagliflozin | Dapagliflozin | Sodium-glucose co-transporter-2 inhibitors | Amputation | Cardiovascular risk | Renal outcomes | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Benzhydryl Compounds - adverse effects | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Risk Assessment | Humans | Amputation - statistics & numerical data | Canagliflozin - adverse effects | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Glucose | Dextrose | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights